A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
- Abstract
- Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. ≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
- All Author(s)
- M. K. Kim
; K. Kim
; C. K. Min
; J. Y. Kwak
; S. B. Bae
; S. S. Yoon
; J. J. Lee
; K. H. Kim
; S. H. Nam
; Y. C. Mun
; H. J. Kim
; S. H. Bae
; H. J. Shin
; J. H. Lee
; J. S. Park
; S. H. Jeong
; M. H. Lee
; Y. S. Kim
; H. S. Lee
; K. W. Park
; W. S. Lee
; S. M. Lee
; J. O. Lee
; M. S. Hyun
; D. Y. Jo
; S. N. Lim
; D. Y. Cho
; Y. R. Do
; J. A. Kim
; S. K. Park
; J. S. Kim
; S. J. Kim
; H. Kim
; H. G. Yi
; J. H. Moon
; C. W. Choi
; S. H. Kim
; Y. D. Joo
; H. G. Kim
; B. S. Kim
; M. R. Park
; M. K. Song
; S. Y. Kim
- Issued Date
- 2017
- Type
- Article
- Keyword
- aged; bortezomib; combination; drug therapy; multiple myeloma
- Publisher
- Impact Journals
- ISSN
- 1949-2553
- Citation Title
- Oncotarget
- Citation Volume
- 8
- Citation Number
- 23
- Citation Start Page
- 37605
- Citation End Page
- 37618
- Language(ISO)
- eng
- DOI
- 10.18632/oncotarget.16790
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2561
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.